Endevica Bio is a world-leader in the discovery of first-in-class peptide drug candidates. Endevica Bio's proprietary technology platform, protected by a robust intellectual property portfolio, allows for the AI-assisted design of novel peptides to modulate activity of previously undrugged G-protein coupled receptors behind the blood-brain barrier, bringing new hope to areas of high unmet medical need.
| Website | http://www.endevicabio.com |
| Employees | 24 (13 on RocketReach) |
| Founded | 2009 |
| Industry | Biotechnology Research |
| Keywords | Peptide Therapeutics, Therapeutic Peptides, Chronic Disease Treatment, Phase 1 Clinical Trials, Clinical Stage, Drug Development, Novel Therapeutics, Medical Research, Biotechnology, Pharmaceutical Research, Clinical Development, Cancer Research, Biopharmaceutical, Oncology, Health |
| Competitors | Bioneer, BioMarin Pharmaceutical Inc., Axovant Sciences Ltd, Audentes Therapeutics, NantKwest, Sangamo Therapeutics, Inc., Plexxikon Inc., CRISPR Therapeutics, ANAVEON AG, CureVac +46 more (view full list) |
Looking for a particular Endevica Bio employee's phone or email?
William Riedl is the Director of Development of Endevica Bio.
13 people are employed at Endevica Bio.
Endevica Bio is based in Northbrook, Illinois.